Vaccination with Rev and Tat against AIDS

被引：94

作者：

Osterhaus, ADME

van Baalen, CA

Gruters, RA

Schutten, M

Siebelink, CHJ

Hulskotte, EGJ

Tijhaar, EJ

Randall, RER

van Amerongen, G

Fleuchaus, A

Erfle, V

Sutter, G

机构：

[1] Eramus Med Ctr Rotterdam, NL-3015 GE Rotterdam, Netherlands

[2] Ecole Normale Super Lyon, UMR103, CNRS Biomerieux, F-69364 Lyon 07, France

[3] Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9ST, Fife, Scotland

[4] GSF, Inst Mol Virol, D-85764 Neurenberg, Germany

来源：

VACCINE | 1999年 / 17卷 / 20-21期

关键词：

D O I：

10.1016/S0264-410X(98)00498-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：2713 / 2714

页数：2

共 8 条

[1] The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate [J].

Conley, AJ ;

Kessler, JA ;

Boots, LJ ;

McKenna, PM ;

Schleif, WA ;

Emini, EA ;

Mark, GE ;

Katinger, H ;

Cobb, EK ;

Lunceford, SM ;

Rouse, SR ;

Murthy, KK .

JOURNAL OF VIROLOGY, 1996, 70 (10) :6751-6758

[2] Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1 [J].

Gauduin, MC ;

Parren, PWHI ;

Weir, R ;

Barbas, CF ;

Burton, DR ;

Koup, RA .

NATURE MEDICINE, 1997, 3 (12) :1389-1393

[3] Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines [J].

Graham, BS ;

McElrath, MJ ;

Connor, RI ;

Schwartz, DH ;

Gorse, GJ ;

Keefer, MC ;

Mulligan, MJ ;

Matthews, TJ ;

Wolinsky, SM ;

Montefiori, DC ;

Vermund, SH ;

Lambert, JS ;

Corey, L ;

Belshe, RB ;

Dolin, R ;

Wright, PF ;

Korber, BT ;

Wolff, MC ;

Fast, PE .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) :310-319

[4] VACCINE-INDUCED VIRUS-NEUTRALIZING ANTIBODIES AND CYTOTOXIC T-CELLS DO NOT PROTECT MACAQUES FROM EXPERIMENTAL-INFECTION WITH SIMIAN IMMUNODEFICIENCY VIRUS SIVMAC32H (J5) [J].

HULSKOTTE, EGJ ;

GERETTI, AM ;

SIEBELINK, KHJ ;

VANAMERONGEN, G ;

CRANAGE, MP ;

RUD, EW ;

NORLEY, SG ;

DEVRIES, P ;

OSTERHAUS, ADME .

JOURNAL OF VIROLOGY, 1995, 69 (10) :6289-6296

[5] Progress in the development of an HIV-1 vaccine [J].

Letvin, NL .

SCIENCE, 1998, 280 (5371) :1875-1880

[6] VIRIONS OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES RESISTANT TO SOLUBLE CD4 (SCD4) NEUTRALIZATION DIFFER IN SCD4 BINDING AND GLYCOPROTEIN GP120 RETENTION FROM SCD4-SENSITIVE ISOLATES [J].

MOORE, JP ;

MCKEATING, JA ;

HUANG, YX ;

ASHKENAZI, A ;

HO, DD .

JOURNAL OF VIROLOGY, 1992, 66 (01) :235-243

[7] Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro [J].

Van Baalen, CA ;

Schutten, M ;

Huisman, RC ;

Boers, PHM ;

Gruters, RA ;

Osterhaus, ADME .

JOURNAL OF VIROLOGY, 1998, 72 (08) :6851-6857

[8] Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS [J].

vanBaalen, CA ;

Pontesilli, O ;

Huisman, RC ;

Geretti, AM ;

Klein, MR ;

deWolf, F ;

Miedema, F ;

Gruters, RA ;

Osterhaus, ADME .

JOURNAL OF GENERAL VIROLOGY, 1997, 78 :1913-1918

← 1 →